These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 35265200)

  • 1. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer.
    Zhou Y; Jin X; Yu H; Qin G; Pan P; Zhao J; Chen T; Liang X; Sun Y; Wang B; Ren D; Zhu S; Wu H
    Theranostics; 2022; 12(5):2080-2094. PubMed ID: 35265200
    [No Abstract]   [Full Text] [Related]  

  • 2. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
    Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
    Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GNG12 regulates PD-L1 expression by activating NF-κB signaling in pancreatic ductal adenocarcinoma.
    Li J; Jin C; Zou C; Qiao X; Ma P; Hu D; Li W; Jin J; Jin X; Fan P
    FEBS Open Bio; 2020 Feb; 10(2):278-287. PubMed ID: 31898405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
    Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
    Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.
    Hu G; He N; Cai C; Cai F; Fan P; Zheng Z; Jin X
    Pancreatology; 2019 Mar; 19(2):383-389. PubMed ID: 30670333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
    Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
    Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis.
    Tsukamoto M; Imai K; Ishimoto T; Komohara Y; Yamashita YI; Nakagawa S; Umezaki N; Yamao T; Kitano Y; Miyata T; Arima K; Okabe H; Baba Y; Chikamoto A; Ishiko T; Hirota M; Baba H
    Cancer Sci; 2019 Jan; 110(1):310-320. PubMed ID: 30426611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy.
    Zhang Z; Cheng L; Li J; Qiao Q; Karki A; Allison DB; Shaker N; Li K; Utturkar SM; Atallah Lanman NM; Rao X; Rychahou P; He D; Konieczny SF; Wang C; Shao Q; Evers BM; Liu X
    Cancer Res; 2022 Oct; 82(19):3532-3548. PubMed ID: 35950917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
    Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS
    Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 13. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma.
    Somani VK; Zhang D; Dodhiawala PB; Lander VE; Liu X; Kang LI; Chen HP; Knolhoff BL; Li L; Grierson PM; Ruzinova MB; DeNardo DG; Lim KH
    Gastroenterology; 2022 Jun; 162(7):2047-2062. PubMed ID: 35271824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.
    Deng Y; Xia X; Zhao Y; Zhao Z; Martinez C; Yin W; Yao J; Hang Q; Wu W; Zhang J; Yu Y; Xia W; Yao F; Zhao D; Sun Y; Ying H; Hung MC; Ma L
    Nat Commun; 2021 Dec; 12(1):7041. PubMed ID: 34873175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
    Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1.
    Fan P; Ma J; Jin X
    Biochem Biophys Res Commun; 2018 Nov; 505(3):830-836. PubMed ID: 30301530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma.
    Liu X; Tang R; Xu J; Tan Z; Liang C; Meng Q; Lei Y; Hua J; Zhang Y; Liu J; Zhang B; Wang W; Yu X; Shi S
    Gut; 2023 Nov; 72(12):2329-2343. PubMed ID: 37541772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
    Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.